Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update

Leap Therapeutics, Inc. (NASDAQ:LPTX) saw a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 1,530,000 shares, adropof25.4% from the July 15th total of 2,050,000 shares. Approximately5.0% of the shares of the company are short sold. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is presently 1.1 days. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately5.0% of the shares of the company are short sold.

Institutional Investors Weigh In On Leap Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. 683 Capital Management LLC lifted its holdings in shares of Leap Therapeutics by 7.4% during the first quarter. 683 Capital Management LLC now owns 1,449,900 shares of the company’s stock worth $442,000 after buying an additional 99,900 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Leap Therapeutics during the fourth quarter worth approximately $4,025,000. Acadian Asset Management LLC lifted its holdings in shares of Leap Therapeutics by 470.4% during the first quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock worth $389,000 after buying an additional 1,056,047 shares during the last quarter. Monaco Asset Management SAM lifted its holdings in shares of Leap Therapeutics by 410.0% during the first quarter. Monaco Asset Management SAM now owns 1,050,000 shares of the company’s stock worth $320,000 after buying an additional 844,126 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Leap Therapeutics by 251.1% during the fourth quarter. Marshall Wace LLP now owns 185,690 shares of the company’s stock worth $535,000 after buying an additional 132,805 shares during the last quarter. 30.46% of the stock is currently owned by institutional investors and hedge funds.

Leap Therapeutics Trading Down 6.3%

Shares of LPTX opened at $0.2684 on Thursday. The business’s 50-day moving average price is $0.33 and its 200 day moving average price is $0.38. The stock has a market capitalization of $11.12 million, a P/E ratio of -0.17 and a beta of -0.27. Leap Therapeutics has a 1-year low of $0.2223 and a 1-year high of $4.79.

Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.11). On average, research analysts predict that Leap Therapeutics will post -1.84 earnings per share for the current year.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.